Researchers at German Center for Neurodegenerative Diseases have identified how neuronal hyperactivity leads to IgLON5 encephalitis, a rare but severe autoimmune brain disorder. Their findings in Science Advances reveal the mechanism behind rogue antibodies and their impact on Tau protein aggregation.
Neuronal hyperactivity has been linked to a severe autoimmune brain disorder known as IgLON5 encephalitis by researchers at the German Center for Neurodegenerative Diseases (DZNE) and Charité—Universitätsmedizin Berlin. This condition, which was first documented in 2014, involves rogue antibodies directed against a cell surface protein called IgLON5 that mistakenly attack cells in the brain.
Until now, it was unclear how these interactions lead to the hallmark symptoms of the disease, including brain inflammation and neuronal damage, manifesting as sleep disturbances, cognitive impairment, and movement disorders. The researchers, led by Prof. Susanne Wegmann from DZNE and Charité, have identified fundamental mechanisms underlying this rare but severe neurodegenerative condition.
Their study, published in Science Advances, revealed that the aberrant antibodies cause IgLON5 proteins to cluster with other molecules on the cell surface, triggering abnormal neuronal hyperactivity. This ultimately leads to Tau mislocalization and aggregation. Previous research has shown that pathological Tau protein aggregation is a major factor in Alzheimer's disease.
Prof. Wegmann explains: "Our findings establish a causal link between the IgLON5 antibodies and Tau pathology. The aberrant clustering of IgLON5 proteins with other molecules on the cell surface leads to neuronal hyperactivity, which then causes Tau mislocalization and aggregation." She adds that this aspect was previously unknown but suggests that alleviating this dysfunction could be a target for future therapies.
IgLON5 autoimmune antibodies (AABs) from patient plasma bind neuronal IgLON5. These findings highlight the potential for developing treatments targeting neuronal hyperactivity as a way to mitigate the disease's progression and alleviate its symptoms.
The condition, also known as Anti-IgLON5 disease, is quite rare but can be fatal if left untreated. Current treatment options include immunosuppression, dialysis, and other approaches, which are not always effective due to the complex nature of the disease.
Understanding the mechanisms behind IgLON5 encephalitis could pave the way for more targeted therapies in the future. The researchers emphasize that their findings provide a critical step towards developing better treatment options for this debilitating condition.
Publication details: Bilge Askin et al, "IgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity," Science Advances (2026). DOI: 10.1126/sciadv.aec2042
Key medical concepts: tau Proteins Alzheimer's Disease Clinical categories Neurology Allergy and immunology
